The question of who owns CRISPR, the genetic editing tool expected to transform modern medicine, is a confusing mess of legal battles, obscure naming conventions, and subtle variations in molecular form and function...
Policy & public
Meet the Heroes You Never Knew You Had
Three Underappreciated Female Pioneers of Synthetic Biology The field of synthetic biology has come a long way from the CRISPR-less days of the early aughts. In 2000, bioengineers made the leap from studying natural...
